Sivraj Muralikrishnan, MD, highlighted top head and neck cancer data from ASCO, including the KEYNOTE-689 trial and the novel mRNA degrader REM-422.
Sivraj Muralikrishnan, MD
Advertisement
Articles by Sivraj Muralikrishnan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
TOP Trial: Chemo-Osimertinib in TP53-Mutant EGFR-Mutated NSCLC
2
How Are CELMoDs Reshaping Treatment in Multiple Myeloma?
3
Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026
4
FLAURA2: Osimertinib Plus Chemo in EGFR-Mutant NSCLC
5